Fluoroquinolone prophylaxis in patients with neutropenia at high risk of serious infections: Exploring pros and cons
Transplant Infectious Disease · 2023
DOI: 10.1111/tid.14152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Nikhil Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia. Hauptthemen laut MEDLINE: Neutropenia, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 113 Literaturangaben.
Abstract (Originalsprache)
Background
The use of fluoroquinolones to prevent infections in neutropenic patients with cancer or undergoing hematopoietic stem cell transplantation (HSCT) is a controversial issue, with international guidelines providing conflicting recommendations. Although potential benefits are clear, concerns revolve around efficacy, potential harms, and antimicrobial resistance (AMR) implications.
Discussion
Fluoroquinolone prophylaxis reduces neutropenic fever (NF) bloodstream infections and other serious bacterial infections, based on evidence from systematic reviews, randomized controlled trials, and observational studies in adults and children. Fluoroquinolone prophylaxis may also reduce infection‐related morbidity and healthcare costs; however, evidence is conflicting. Adverse effects of fluoroquinolones are well recognized in the general population; however, studies in the cancer cohort where it is used for a defined period of neutropenia have not reflected this. The largest concern for routine use of fluoroquinolone prophylaxis remains AMR, as many, but not all, observational studies have found that fluoroquinolone prophylaxis might increase the risk of AMR, and some studies have suggested negative impacts on patient outcomes as a result.
Conclusions
The debate surrounding fluoroquinolone prophylaxis calls for individualized risk assessment based on patient characteristics and local AMR patterns, and prophylaxis should be restricted to patients at the highest risk of serious infection during the highest risk periods to ensure that the risk‐benefit analysis is in favor of individual and community benefit. More research is needed to address important unanswered questions about fluoroquinolone prophylaxis in neutropenic patients with cancer or receiving HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
- Department of Infectious Diseases, Melbourne Medical School, University of Melbourne, Melbourne, Australia.
- National Centre for Antimicrobial Stewardship, Department of Infectious Diseases, University of Melbourne, Melbourne, Australia.
ORCID-Profile: Joshua Wolf
Zitieren
APA
Singh, N., Thursky, K., Maron, G., & Wolf, J. (2023). Fluoroquinolone prophylaxis in patients with neutropenia at high risk of serious infections: Exploring pros and cons. Transplant Infectious Disease. https://doi.org/10.1111/tid.14152
Vancouver
Singh N, Thursky K, Maron G, Wolf J. Fluoroquinolone prophylaxis in patients with neutropenia at high risk of serious infections: Exploring pros and cons. Transplant Infectious Disease. 2023. doi:10.1111/tid.14152
BibTeX
@article{Singh2023,
author = {Singh, Nikhil and Thursky, Karin and Maron, Gabriela and Wolf, Joshua},
title = {Fluoroquinolone prophylaxis in patients with neutropenia at high risk of serious infections: Exploring pros and cons},
journal = {Transplant Infectious Disease},
year = {2023},
doi = {10.1111/tid.14152}
}
EUVIMED